No Data
Lepu Biopharma Renews Procurement Contract With Controlling Shareholder
Lepu Biotechnology-B(02157.HK) and Lepu Medical Technology have signed a CDMO service framework agreement.
Gelonghui November 26th丨Lepu Biopharmaceutical-B (02157.HK) announced that on November 26, 2024, the company entered into a CDMO service framework agreement with lepu medical technology, under which the company and/or its subsidiaries agree to provide CDMO technical services and related supporting equipment to lepu medical technology and/or its subsidiaries.
Hong Kong stock market anomaly | Xintai Medical (02291) surged more than 30% in the morning session, recently renewed a framework agreement with Lepu Medical Technology, and the trading volume may increase year by year in the next three years.
Heartai Medical (02291) rose over 30% in early trading, as of the time of writing, up 30.92%, priced at HKD 22.1, with a trading volume of HKD 19.5613 million.
Express News | lepu medical technology: Subsidiaries MWN105 injection, MWN109 injection obtained the drug clinical trial approval notice.
Lepu Medical Technology (300003): The impact of channel adjustments in the pharmaceutical sector is expected to come to an end. Innovative medical devices continue to maintain high growth.
Investment Highlights: The company released the third quarter report for 2024. In Q1-Q3 2024, the company achieved revenue of 4.785 billion yuan (-23.55% year-on-year), net income attributable to the parent company of 0.803 billion yuan (-40.70% year-on-year), net of non-recurring gains and losses.
Major MSCI adjustment! Brokerage stocks are most favored, 20 companies are being removed.
On November 7th, Beijing time, the international index compiler MSCI announced the results of the November stock index review. Among them, 4 Chinese stocks were newly included in the MSCI China Index, while 20 individual stocks were removed. All changes will take effect after the market closes on November 25, 2024.
No Data
No Data